Atrial Fibrillation Drugs Market 2027 by Types, Application, Technology, Opportunities, End Users and Regions | The Insight Partners

Atrial Fibrillation Drugs Market to 2027 - Global Analysis and Forecasts By Product (Anticoagulant Drugs, Antiarrhythmic Drugs); Type (Permanent, Persistent, Paroxysmal); Application (Heart Rate Control, Heart Rhythm Control); End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers) and Geography

Report Code: TIPRE00005207 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Atrial fibrillation is an irregular heartbeat that can lead to blood clots, heart failure & other heart - related complications. Abnormality and damage to the heart structure are the most common causes of atrial fibrillation as well as possible causes of it include high blood pressure, heart attack. It causes by degeneration of the electrical impulse in the upper cardiac chamber of the leading to chaotic rhythm. The atrial fibrillation drug used to maintain heart rate by preventing bold clots which are responsible for it.

MARKET DYNAMICS
The atrial fibrillation drugs market is expected to drive in the forecast period due to the key driving factors such as changing life style and alcohol consumption, rising geriatric population, prevalence of cardiovascular disease, increase diabetic population, awareness related to heart disease and others. In addition, various players in the emerging market have strong pipeline product and high potential which are anticipated to create several growth opportunities for the market during the forecast period.

MARKET SCOPE
The "Global Atrial Fibrillation Drugs Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of atrial fibrillation drugs market with detailed market segmentation by product, type, application, end user and geography. The global atrial fibrillation drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading the atrial fibrillation drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global atrial fibrillation drugs market is segmented on the basis of product, type, application and end user. Based on products, the market is segmented as anticoagulant drugs and antiarrhythmic drugs. On the basis of type, the global atrial fibrillation drugs market is segmented into permanent, persistent and paroxysmal. Based on the application the market is segmented into heart rate control and heart rhythm control. On the basis of end user the market is classify into hospitals, cardiac centers and ambulatory surgical centers.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global atrial fibrillation drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The atrial fibrillation drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting atrial fibrillation drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the atrial fibrillation drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the atrial fibrillation drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from atrial fibrillation drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for atrial fibrillation drugs in the global market. Below mentioned is the list of few companies engaged in the atrial fibrillation drugs market.
The report also includes the profiles of key atrial fibrillation drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Pfizer
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Bristol-Myers Squibb Company
  • Mitsubishi Tanabe Pharma Corporation
  • Johnson and Johnson
  • DAIICHI SANKYO COMPANY, LIMITED
  • GlaxoSmithKline plc
  • Portola Pharmaceuticals
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Atrial Fibrillation Drugs Market - By Product
1.3.2 Atrial Fibrillation Drugs Market - By Type
1.3.3 Atrial Fibrillation Drugs Market - By Application
1.3.4 Atrial Fibrillation Drugs Market - By End User
1.3.5 Atrial Fibrillation Drugs Market - By Region
1.3.5.1 by Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ATRIAL FIBRILLATION DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ATRIAL FIBRILLATION DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ATRIAL FIBRILLATION DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ATRIAL FIBRILLATION DRUGS - GLOBAL MARKET OVERVIEW
6.2. ATRIAL FIBRILLATION DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. ATRIAL FIBRILLATION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. ANTICOAGULANT DRUGS
7.3.1. Overview
7.3.2. Anticoagulant Drugs Market Forecast and Analysis
7.4. ANTIARRHYTHMIC DRUGS
7.4.1. Overview
7.4.2. Antiarrhythmic Drugs Market Forecast and Analysis
8. ATRIAL FIBRILLATION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - TYPE
8.1. OVERVIEW
8.2. TYPE MARKET FORECASTS AND ANALYSIS
8.3. PERMANENT
8.3.1. Overview
8.3.2. Permanent Market Forecast and Analysis
8.4. PERSISTENT
8.4.1. Overview
8.4.2. Persistent Market Forecast and Analysis
8.5. PAROXYSMAL
8.5.1. Overview
8.5.2. Paroxysmal Market Forecast and Analysis
9. ATRIAL FIBRILLATION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. HEART RATE CONTROL
9.3.1. Overview
9.3.2. Heart Rate Control Market Forecast and Analysis
9.4. HEART RHYTHM CONTROL
9.4.1. Overview
9.4.2. Heart Rhythm Control Market Forecast and Analysis
10. ATRIAL FIBRILLATION DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS
10.3.1. Overview
10.3.2. Hospitals Market Forecast and Analysis
10.4. CARDIAC CENTERS
10.4.1. Overview
10.4.2. Cardiac Centers Market Forecast and Analysis
10.5. AMBULATORY SURGICAL CENTERS
10.5.1. Overview
10.5.2. Ambulatory Surgical Centers Market Forecast and Analysis
11. ATRIAL FIBRILLATION DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Atrial Fibrillation Drugs Market Overview
11.1.2 North America Atrial Fibrillation Drugs Market Forecasts and Analysis
11.1.3 North America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Product
11.1.4 North America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Type
11.1.5 North America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Application
11.1.6 North America Atrial Fibrillation Drugs Market Forecasts and Analysis - By End User
11.1.7 North America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Countries
11.1.7.1 United States Atrial Fibrillation Drugs Market
11.1.7.1.1 United States Atrial Fibrillation Drugs Market by Product
11.1.7.1.2 United States Atrial Fibrillation Drugs Market by Type
11.1.7.1.3 United States Atrial Fibrillation Drugs Market by Application
11.1.7.1.4 United States Atrial Fibrillation Drugs Market by End User
11.1.7.2 Canada Atrial Fibrillation Drugs Market
11.1.7.2.1 Canada Atrial Fibrillation Drugs Market by Product
11.1.7.2.2 Canada Atrial Fibrillation Drugs Market by Type
11.1.7.2.3 Canada Atrial Fibrillation Drugs Market by Application
11.1.7.2.4 Canada Atrial Fibrillation Drugs Market by End User
11.1.7.3 Mexico Atrial Fibrillation Drugs Market
11.1.7.3.1 Mexico Atrial Fibrillation Drugs Market by Product
11.1.7.3.2 Mexico Atrial Fibrillation Drugs Market by Type
11.1.7.3.3 Mexico Atrial Fibrillation Drugs Market by Application
11.1.7.3.4 Mexico Atrial Fibrillation Drugs Market by End User
11.2. EUROPE
11.2.1 Europe Atrial Fibrillation Drugs Market Overview
11.2.2 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis
11.2.3 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis - By Product
11.2.4 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis - By Type
11.2.5 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis - By Application
11.2.6 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis - By End User
11.2.7 Europe Atrial Fibrillation Drugs Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Atrial Fibrillation Drugs Market
11.2.7.1.1 Germany Atrial Fibrillation Drugs Market by Product
11.2.7.1.2 Germany Atrial Fibrillation Drugs Market by Type
11.2.7.1.3 Germany Atrial Fibrillation Drugs Market by Application
11.2.7.1.4 Germany Atrial Fibrillation Drugs Market by End User
11.2.7.2 France Atrial Fibrillation Drugs Market
11.2.7.2.1 France Atrial Fibrillation Drugs Market by Product
11.2.7.2.2 France Atrial Fibrillation Drugs Market by Type
11.2.7.2.3 France Atrial Fibrillation Drugs Market by Application
11.2.7.2.4 France Atrial Fibrillation Drugs Market by End User
11.2.7.3 Italy Atrial Fibrillation Drugs Market
11.2.7.3.1 Italy Atrial Fibrillation Drugs Market by Product
11.2.7.3.2 Italy Atrial Fibrillation Drugs Market by Type
11.2.7.3.3 Italy Atrial Fibrillation Drugs Market by Application
11.2.7.3.4 Italy Atrial Fibrillation Drugs Market by End User
11.2.7.4 Spain Atrial Fibrillation Drugs Market
11.2.7.4.1 Spain Atrial Fibrillation Drugs Market by Product
11.2.7.4.2 Spain Atrial Fibrillation Drugs Market by Type
11.2.7.4.3 Spain Atrial Fibrillation Drugs Market by Application
11.2.7.4.4 Spain Atrial Fibrillation Drugs Market by End User
11.2.7.5 United Kingdom Atrial Fibrillation Drugs Market
11.2.7.5.1 United Kingdom Atrial Fibrillation Drugs Market by Product
11.2.7.5.2 United Kingdom Atrial Fibrillation Drugs Market by Type
11.2.7.5.3 United Kingdom Atrial Fibrillation Drugs Market by Application
11.2.7.5.4 United Kingdom Atrial Fibrillation Drugs Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Atrial Fibrillation Drugs Market Overview
11.3.2 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis
11.3.3 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis - By Product
11.3.4 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis - By Type
11.3.5 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Atrial Fibrillation Drugs Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Atrial Fibrillation Drugs Market
11.3.7.1.1 Australia Atrial Fibrillation Drugs Market by Product
11.3.7.1.2 Australia Atrial Fibrillation Drugs Market by Type
11.3.7.1.3 Australia Atrial Fibrillation Drugs Market by Application
11.3.7.1.4 Australia Atrial Fibrillation Drugs Market by End User
11.3.7.2 China Atrial Fibrillation Drugs Market
11.3.7.2.1 China Atrial Fibrillation Drugs Market by Product
11.3.7.2.2 China Atrial Fibrillation Drugs Market by Type
11.3.7.2.3 China Atrial Fibrillation Drugs Market by Application
11.3.7.2.4 China Atrial Fibrillation Drugs Market by End User
11.3.7.3 India Atrial Fibrillation Drugs Market
11.3.7.3.1 India Atrial Fibrillation Drugs Market by Product
11.3.7.3.2 India Atrial Fibrillation Drugs Market by Type
11.3.7.3.3 India Atrial Fibrillation Drugs Market by Application
11.3.7.3.4 India Atrial Fibrillation Drugs Market by End User
11.3.7.4 Japan Atrial Fibrillation Drugs Market
11.3.7.4.1 Japan Atrial Fibrillation Drugs Market by Product
11.3.7.4.2 Japan Atrial Fibrillation Drugs Market by Type
11.3.7.4.3 Japan Atrial Fibrillation Drugs Market by Application
11.3.7.4.4 Japan Atrial Fibrillation Drugs Market by End User
11.3.7.5 South Korea Atrial Fibrillation Drugs Market
11.3.7.5.1 South Korea Atrial Fibrillation Drugs Market by Product
11.3.7.5.2 South Korea Atrial Fibrillation Drugs Market by Type
11.3.7.5.3 South Korea Atrial Fibrillation Drugs Market by Application
11.3.7.5.4 South Korea Atrial Fibrillation Drugs Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Atrial Fibrillation Drugs Market Overview
11.4.2 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis
11.4.3 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis - By Product
11.4.4 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis - By Type
11.4.5 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Atrial Fibrillation Drugs Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Atrial Fibrillation Drugs Market
11.4.7.1.1 South Africa Atrial Fibrillation Drugs Market by Product
11.4.7.1.2 South Africa Atrial Fibrillation Drugs Market by Type
11.4.7.1.3 South Africa Atrial Fibrillation Drugs Market by Application
11.4.7.1.4 South Africa Atrial Fibrillation Drugs Market by End User
11.4.7.2 Saudi Arabia Atrial Fibrillation Drugs Market
11.4.7.2.1 Saudi Arabia Atrial Fibrillation Drugs Market by Product
11.4.7.2.2 Saudi Arabia Atrial Fibrillation Drugs Market by Type
11.4.7.2.3 Saudi Arabia Atrial Fibrillation Drugs Market by Application
11.4.7.2.4 Saudi Arabia Atrial Fibrillation Drugs Market by End User
11.4.7.3 U.A.E Atrial Fibrillation Drugs Market
11.4.7.3.1 U.A.E Atrial Fibrillation Drugs Market by Product
11.4.7.3.2 U.A.E Atrial Fibrillation Drugs Market by Type
11.4.7.3.3 U.A.E Atrial Fibrillation Drugs Market by Application
11.4.7.3.4 U.A.E Atrial Fibrillation Drugs Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Atrial Fibrillation Drugs Market Overview
11.5.2 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis
11.5.3 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Product
11.5.4 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Type
11.5.5 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Application
11.5.6 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis - By End User
11.5.7 South and Central America Atrial Fibrillation Drugs Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Atrial Fibrillation Drugs Market
11.5.7.1.1 Brazil Atrial Fibrillation Drugs Market by Product
11.5.7.1.2 Brazil Atrial Fibrillation Drugs Market by Type
11.5.7.1.3 Brazil Atrial Fibrillation Drugs Market by Application
11.5.7.1.4 Brazil Atrial Fibrillation Drugs Market by End User
11.5.7.2 Argentina Atrial Fibrillation Drugs Market
11.5.7.2.1 Argentina Atrial Fibrillation Drugs Market by Product
11.5.7.2.2 Argentina Atrial Fibrillation Drugs Market by Type
11.5.7.2.3 Argentina Atrial Fibrillation Drugs Market by Application
11.5.7.2.4 Argentina Atrial Fibrillation Drugs Market by End User
11.5.7.3 Chile Atrial Fibrillation Drugs Market
11.5.7.3.1 Chile Atrial Fibrillation Drugs Market by Product
11.5.7.3.2 Chile Atrial Fibrillation Drugs Market by Type
11.5.7.3.3 Chile Atrial Fibrillation Drugs Market by Application
11.5.7.3.4 Chile Atrial Fibrillation Drugs Market by End User
11.5.7.4 Costa Rica Atrial Fibrillation Drugs Market
11.5.7.4.1 Costa Rica Atrial Fibrillation Drugs Market by Product
11.5.7.4.2 Costa Rica Atrial Fibrillation Drugs Market by Type
11.5.7.4.3 Costa Rica Atrial Fibrillation Drugs Market by Application
11.5.7.4.4 Costa Rica Atrial Fibrillation Drugs Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. ATRIAL FIBRILLATION DRUGS MARKET, KEY COMPANY PROFILES
13.1. PFIZER
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ASTRAZENECA
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. SANOFI
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. BRISTOL-MYERS SQUIBB COMPANY
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MITSUBISHI TANABE PHARMA CORPORATION
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. JOHNSON AND JOHNSON
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. DAIICHI SANKYO COMPANY, LIMITED
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GLAXOSMITHKLINE PLC
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. PORTOLA PHARMACEUTICALS
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer
2. AstraZeneca
3. Boehringer Ingelheim International GmbH
4. Sanofi
5. Bristol-Myers Squibb Company
6. Mitsubishi Tanabe Pharma Corporation
7. Johnson and Johnson
8. DAIICHI SANKYO COMPANY, LIMITED
9. GlaxoSmithKline plc
10. Portola Pharmaceuticals